We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05381935
Recruitment Status : Not yet recruiting
First Posted : May 19, 2022
Last Update Posted : August 8, 2022
Sponsor:
Information provided by (Responsible Party):
Elpiscience Biopharma, Ltd.

Tracking Information
First Submitted Date  ICMJE May 11, 2022
First Posted Date  ICMJE May 19, 2022
Last Update Posted Date August 8, 2022
Estimated Study Start Date  ICMJE April 21, 2023
Estimated Primary Completion Date April 30, 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 16, 2022)
  • The frequency and severity of adverse events of ES014 [ Time Frame: 1-3 years ]
    Adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. [Time Frame: 1-3 years]
  • Dose Limiting Toxicity of ES014 [ Time Frame: Assessed during first 28 days of treatment ]
    Evaluation of dose-limiting toxicity (DLT)
  • Optimal biological dose (OBD) of ES014 [ Time Frame: 1-3 years ]
    The OBD of ES014 will be determined
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 16, 2022)
  • Maximum observed serum concentration (Cmax) of ES014 [ Time Frame: 1-3 years ]
    Maximum observed serum concentration (Cmax) of ES014 will be measured.
  • Trough observed serum concentration (Ctrough) of ES014 [ Time Frame: 1-3 years ]
    Trough observed serum concentration (Ctrough)of ES014 will be measured.
  • Area under the serum concentration time curve (AUC) of ES014 [ Time Frame: 1-3 years ]
    Area under the serum concentration time curve (AUC) of ES014 will be measured
  • Time to Cmax (Tmax) of ES014 [ Time Frame: 1-3 years ]
    Time to Cmax (Tmax) of ES014 will be measured
  • The terminal elimination half life of ES014 [ Time Frame: 1-3 years ]
    The terminal elimination half-life (t 1/2) of ES014 will be measured
  • The clearance of ES014 [ Time Frame: 1-3 years ]
    A pharmacokinetic measurement of the volume of plasma from which ES014 is completely removed per unit time
  • The volume of distribution of ES014 [ Time Frame: 1-3 years ]
    The amount of of ES014 in the body divided by the plasma concentration will be measured
  • The immunogenicity of ES014 [ Time Frame: 1-3 years ]
    The presence and the frequency of anti-drug antibodies (ADA) against ES014 will be measured
  • The antitumor activity of ES014 [ Time Frame: 1-3 years ]
    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Official Title  ICMJE An Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion, Phase 1 Study of ES014 in Subjects With Locally Advanced or Metastatic Solid Tumors
Brief Summary The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.
Detailed Description Adenosine and transforming growth factor-β (TGF-β) are two key immune suppressors in the tumor microenvironment (TME) that cause broad immune suppression resulting in resistance to current checkpoint inhibitor immunotherapies. The bifunctional antibody-fusion protein ES014 was created by fusing the TGF-β receptor II ectodomain to an antibody targeting human ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1, CD39, UniprotKB: P49961). ES014 simultaneously neutralizes autocrine/paracrine TGF-β and inhibits the enzymatic activity of CD39, which results in the stabilization of pro-inflammatory extracellular adenosine triphosphate (eATP) and the restoration of anti-tumor immunity by impairing the accumulation of immune suppressive adenosine and TGF-β within the TME.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumor
Intervention  ICMJE Drug: ES014
ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study Arms  ICMJE
  • Experimental: Part 1 dose escalation
    ES014 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
    Intervention: Drug: ES014
  • Experimental: Part 2 dose expansion
    Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
    Intervention: Drug: ES014
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: May 16, 2022)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 30, 2026
Estimated Primary Completion Date April 30, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria

  1. To be eligible for study entry, subjects must satisfy all of the following criteria:
  2. Capable of giving signed informed consent.
  3. Part 1: Histological or cytological documentation of unresectable locally advanced or metastatic solid tumors, if 1) disease has progressed despite standard therapy, and no further standard therapy exists; or 2) standard therapy has proven to be ineffective or intolerable.

    Part 2: Histological or cytological documentation of PDAC (Cohort 2A), CRC (Cohort 2B), or NSCLC (Cohort 2C), with unresectable locally advanced or metastatic disease, if 1) disease has progressed despite standard therapy, and no further standard therapy exists; or 2) standard therapy has proven to be ineffective or intolerable.

  4. Provide tumor tissue samples (minimum 10 unstained FFPE slides) obtained from the initial diagnosis to study entry.
  5. At least one measurable lesion per RECIST v1.1.
  6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

    • Part 1: ECOG PS 0-1.
    • Part 2: ECOG PS 0-2.
  7. Life expectancy of at least 12 weeks.
  8. Adequate hematologic, hepatic, renal and coagulation functions per protocol
  9. Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception

Key Exclusion Criteria

  1. Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.
  2. Receipt of any investigational agents or devices within 4 weeks prior to the first dose of study drug.
  3. Prior treatment with the following therapies:

    1. Anticancer therapy within 30 days or 5 half-lives of the drug prior to the first dose of study drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered. Exception: hormonal and/or hormonal replacement therapy.
    2. A wash out of at least 2 weeks before the start of study drug for radiation to the extremities and 4 weeks for radiation to the chest, brain, or visceral organs is required.
  4. Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.
  5. Toxicity from previous anticancer treatment per protocol.
  6. Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug.
  7. Subjects who received transfusion of blood products (including platelets or red blood cells), G-CSF, GM-CSF, recombinant erythropoietin, or recombinant thrombopoietin within 14 days prior to the first dose of study treatment.
  8. Major surgery within 4 weeks prior to the first dose of study treatment.
  9. Live vaccine therapies within 4 weeks prior to the first dose of study treatment.
  10. Recent history of allergen desensitization therapy within 4 weeks prior to the first dose of study treatment.
  11. Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES014.
  12. Invasive malignancy or history of invasive malignancy other than disease under study within the last two years per protocol.
  13. CNS metastases.
  14. Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications per protocol.
  15. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  16. Active infection requiring systemic therapy, known human immunodeficiency virus (HIV) infection, or positive test for hepatitis B active infection (HBsAg) or hepatitis C active infection (hepatitis C antibody).
  17. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment).
  18. History or evidence of cardiac abnormalities per protocol.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Clinical Development (+86) 21 50651310 Clinical.Development@elpiscience.com
Contact: Clinical Development
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05381935
Other Study ID Numbers  ICMJE ES014-1001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Elpiscience Biopharma, Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Elpiscience Biopharma, Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Elpiscience Biopharma, Ltd. Elpiscience Biopharma, Ltd.
PRS Account Elpiscience Biopharma, Ltd.
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP